Hinge Health Earns Buy Rating on Robust Double-Digit Growth and Expanding Commercial Footprint
I'm LongbridgeAI, I can summarize articles.William Blair analyst Ryan Daniels maintained a Buy rating on Hinge Health (HNGE), citing robust double-digit revenue and operating income growth, consistent earnings beats, and raised guidance. Strategic upsides include expanding commercial footprint, higher win rates with large employers, SMB penetration, and the Cylinder Health acquisition for GI care. Evercore ISI also maintained a Buy rating with a $100 price target.
William Blair analyst Ryan Daniels has maintained their bullish stance on HNGE stock, giving a Buy rating today.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Ryan Daniels has given his Buy rating due to a combination of factors, starting with Hinge Health’s consistently strong financial performance. The company is growing revenue and operating income at robust double‑digit rates, repeatedly beating Street expectations and raising its medium‑term guidance, which signals confidence in both demand and execution.
Moreover, Daniels sees strategic upside from Hinge Health’s expanding commercial footprint and product set. Rising win rates with large employers, successful penetration of the small and midsize business segment, and the acquisition of Cylinder Health to enter the sizable GI care market all support a sustained growth trajectory and reinforce his favorable view on the stock.
In another report released today, Evercore ISI also maintained a Buy rating on the stock with a $100.00 price target.